{"id":821634,"date":"2025-03-04T16:16:17","date_gmt":"2025-03-04T21:16:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/"},"modified":"2025-03-04T16:16:17","modified_gmt":"2025-03-04T21:16:17","slug":"eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/","title":{"rendered":"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference"},"content":{"rendered":"
\n

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT).<\/p>\n

To register in advance for the fireside chat webcast, sign up\u00a0here<\/a>.<\/p>\n

A webcast replay will be accessible following the live session on the Company\u2019s website under Events<\/a>.<\/p>\n

\n About\u00a0Eledon Pharmaceuticals\u00a0and tegoprubart<\/strong>\n <\/p>\n

Eledon Pharmaceuticals, Inc.\u00a0is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company\u2019s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in\u00a0Irvine,\u00a0California. For more information, please visit the Company\u2019s website at\u00a0www.eledon.com<\/a>.<\/p>\n

Follow\u00a0Eledon Pharmaceuticals\u00a0on social media:\u00a0LinkedIn<\/a>;\u00a0Twitter<\/a><\/p>\n

\n Investor Contact:<\/strong>\n <\/p>\n

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com<\/a><\/p>\n

\n Media Contact:<\/strong>\n <\/p>\n

Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com<\/a><\/p>\n

Source:\u00a0Eledon Pharmaceuticals<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up\u00a0here. A webcast replay will be accessible following the live session on the Company\u2019s website under Events. About\u00a0Eledon Pharmaceuticals\u00a0and tegoprubart Eledon Pharmaceuticals, Inc.\u00a0is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company\u2019s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a … <\/p>\n

Continue reading “Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-821634","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up\u00a0here. A webcast replay will be accessible following the live session on the Company\u2019s website under Events. About\u00a0Eledon Pharmaceuticals\u00a0and tegoprubart Eledon Pharmaceuticals, Inc.\u00a0is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company\u2019s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a … Continue reading "Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-04T21:16:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODQ1OCM2Nzg5MjM2IzIwMDY1NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference\",\"datePublished\":\"2025-03-04T21:16:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/\"},\"wordCount\":246,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODQ1OCM2Nzg5MjM2IzIwMDY1NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/\",\"name\":\"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODQ1OCM2Nzg5MjM2IzIwMDY1NTA=\",\"datePublished\":\"2025-03-04T21:16:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODQ1OCM2Nzg5MjM2IzIwMDY1NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4ODQ1OCM2Nzg5MjM2IzIwMDY1NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference - Market Newsdesk","og_description":"IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (\u201cEledon\u201d) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET (11:20 a.m. PT). To register in advance for the fireside chat webcast, sign up\u00a0here. A webcast replay will be accessible following the live session on the Company\u2019s website under Events. About\u00a0Eledon Pharmaceuticals\u00a0and tegoprubart Eledon Pharmaceuticals, Inc.\u00a0is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company\u2019s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a … Continue reading \"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-04T21:16:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODQ1OCM2Nzg5MjM2IzIwMDY1NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference","datePublished":"2025-03-04T21:16:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/"},"wordCount":246,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODQ1OCM2Nzg5MjM2IzIwMDY1NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/","name":"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODQ1OCM2Nzg5MjM2IzIwMDY1NTA=","datePublished":"2025-03-04T21:16:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODQ1OCM2Nzg5MjM2IzIwMDY1NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4ODQ1OCM2Nzg5MjM2IzIwMDY1NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eledon-pharmaceuticals-to-participate-in-leerink-partners-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821634","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=821634"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/821634\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=821634"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=821634"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=821634"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}